/** Supplemental SSR sections for standalone /healthcare-market-research-{country} pages below 2,000 words. */

export type HealthcareMrDepthSection = {
  id: string;
  title: string;
  paragraphs: string[];
  bullets?: string[];
};

export type HealthcareMrCountryDepth = {
  hubLinkLabel: string;
  sections: HealthcareMrDepthSection[];
};

export const HEALTHCARE_MR_COUNTRY_DEPTH: Record<string, HealthcareMrCountryDepth> = {
  netherlands: {
    hubLinkLabel: 'healthcare market research hub',
    sections: [
      {
        id: 'decision-blueprint',
        title: 'Decision blueprint: why Dutch teams commission primary research',
        paragraphs: [
          'Dutch pharmaceutical and medtech affiliates rarely lack syndicated audit rows — they lack clarity on how Zorginstituut Nederland GVS recommendations, individual health-insurer negotiation, and hospital formulary behaviour combine before a launch budget is released. BioNixus anchors each Netherlands programme on one decision: formulary sequencing, KOL prioritisation, GVS evidence planning, or competitive defence when biosimilar preference policies accelerate switching.',
          'Mixed-method designs pair quantitative HCP surveys with health-insurer depth interviews and pharmacy substitution modules so leadership sees both the metric and the operational reason — prior-authorization burden, nurse infusion capacity, or pharmacist-led interchangeability — rather than a single national average that hides account-level variance.',
        ],
        bullets: [
          'METC- and CCMO-compliant protocols with UAVG-aligned patient modules when caregivers are in scope',
          'Academic centre coverage across Amsterdam UMC, Erasmus MC, UMC Utrecht, and Leiden UMC plus community clusters',
          'Optional EU5 and UK benchmarking cells using harmonised instruments for regional portfolio reviews',
        ],
      },
      {
        id: 'payer-formulary',
        title: 'Payer and formulary intelligence beyond the CBG-MEB label',
        paragraphs: [
          'Marketing authorisation from CBG-MEB opens the market; commercial outcomes depend on GVS placement, insurer-specific coverage criteria, and NZa oversight of tariffs and conduct. Research must document which evidence formats accelerate committee approval — budget impact, patient-reported outcomes, or real-world utilisation — and which objections recur after a positive GVS opinion.',
          'BioNixus runs paired physician–payer modules, simulated advisory discussions, and formulary objection libraries tied to observable administration patterns. Outputs connect to the pharmaceutical market research Netherlands page and top healthcare MR company guides when affiliates need a ranked vendor shortlist alongside fieldwork.',
        ],
      },
      {
        id: 'programme-deliverables',
        title: 'Programme timeline, deliverables, and governance',
        paragraphs: [
          'Focused HCP survey modules typically complete in three to four weeks after protocol sign-off; mixed-method programmes with health-insurer interviews, advisory-style discussions, or paired physician–payer cells run six to ten weeks depending on therapy area, METC review requirements, and respondent scarcity. BioNixus documents feasibility and recruitment risk in writing before fieldwork scales so affiliates do not discover sample gaps mid-wave.',
          'Deliverables include an executive synthesis mapped to one commercial or access decision, segment dossiers with behavioural rationale, objection libraries tied to decision stage, and optional workshop facilitation so medical, access, and brand teams translate findings without weeks of reinterpretation. Methodology appendices support internal compliance review and can be shared with medical affairs when external engagement rules apply.',
          'For multinational portfolios, Dutch cells can run in parallel with UK, EU5, USA, Brazil, or GCC modules using harmonised instruments — preserving local access realism while giving regional committees comparable metrics. Request a scoped proposal via the contact form; most engagements receive a costed methodology outline within 48 hours once objectives, audience, and geography are defined.',
          'Governance: EphMRA- and BHBIA-aligned study design, METC/CCMO ethics where required, UAVG-aligned patient modules, specialty-verified HCP samples, and secure data handling with audit-ready methodology documentation for affiliate compliance teams.',
        ],
      },
    ],
  },
  spain: {
    hubLinkLabel: 'healthcare market research hub',
    sections: [
      {
        id: 'decision-blueprint',
        title: 'How pharmaceutical teams use primary research in Spain',
        paragraphs: [
          'Spain combines autonomous regional health systems with national AEMPS authorisation and fragmented pricing and reimbursement negotiation. Affiliates commission BioNixus when launch sequencing, hospital prioritisation, or biosimilar defence requires prescriber, pharmacist, and payer behaviour — not desk extrapolation from EU5 averages.',
          'Studies stratify by autonomous community where procurement and access diverge, while preserving comparable cores for Iberian and EU portfolio committees. Fieldwork follows GDPR and local ethics expectations with specialty-verified HCP samples and documented informed consent.',
        ],
        bullets: [
          'Hospital pharmacy and therapeutics committee research for high-cost and specialty products',
          'Regional payer and pricing intelligence aligned with real-world HTA and financing routes',
          'KOL mapping at major academic hospitals in Madrid, Barcelona, Valencia, and Seville clusters',
        ],
      },
      {
        id: 'access-realism',
        title: 'Access realism for launches and lifecycle defence',
        paragraphs: [
          'Spanish uptake often stalls on step therapy documentation, hospital budget caps, and pharmacist substitution confidence — not on clinical rejection alone. BioNixus quantifies where prior authorization friction suppresses eligible patients and which medical education or services investments change persistence.',
          'For manufacturers exporting from Spain into GCC markets, modules can link Iberian evidence to SFDA and MOHAP access questions — see the healthcare market research hub for cross-regional sequencing.',
        ],
      },
      {
        id: 'programme-deliverables',
        title: 'Programme timeline and deliverables in Spain',
        paragraphs: [
          'Quantitative waves with autonomous-community stratification typically run four to six weeks; programmes adding hospital committee interviews or paired pharmacist modules extend to eight to ten weeks when oncology, immunology, or rare disease samples are scarce. Feasibility memos document recruitment risk before protocols finalise.',
          'Deliverables emphasise segment prioritisation by region, uptake scenarios grounded in surveyed behaviour, and executive summaries linking evidence gaps to access owners — plus methodology appendices suitable for affiliate governance. Parallel Iberian and EU5 cells use harmonised cores when portfolio committees need comparable metrics without losing regional access realism.',
          'Governance follows GDPR and local ethics requirements, EphMRA-aligned pharmaceutical research standards, specialty-verified HCP and pharmacist samples, and de-identified reporting suitable for medical affairs review. Proposal turnaround is typically 48 hours after objectives, audience, and autonomous-community scope are confirmed.',
        ],
      },
      {
        id: 'therapy-modules',
        title: 'Therapy-area modules commonly fielded in Spain',
        paragraphs: [
          'Oncology and haematology programmes stratify by autonomous community and centre type — public tertiary hubs versus private networks — measuring tumour-board sequencing, biomarker testing friction, and hospital budget gates that delay labelled eligibility. Immunology and dermatology modules capture step-therapy documentation burdens and pharmacist substitution confidence that suppress biologic uptake despite specialist intent.',
          'Cardiometabolic and GLP-1 portfolios require primary-care versus specialist handoff research because persistence often sits with community prescribers after hospital initiation. Rare disease modules build bottom-up diagnosed cohorts rather than epidemiology-alone forecasts, mapping referral lag and regional funding exceptions that shrink treatable populations.',
          'Each module connects to therapy hubs on the healthcare market research programme and to pharmaceutical market research Spain when the brief is manufacturer-focused rather than services-only.',
        ],
      },
    ],
  },
  canada: {
    hubLinkLabel: 'healthcare market research hub',
    sections: [
      {
        id: 'decision-blueprint',
        title: 'Canadian healthcare market research: provincial reality first',
        paragraphs: [
          'Canada’s publicly funded system routes decisions through provincial formularies, CADTH health technology assessment, and pCPA negotiation — national approval does not imply uniform access. BioNixus designs research backward from the province or account archetype that will carry your revenue, not from a single “Canada average” that obscures Quebec versus Ontario versus Alberta dynamics.',
          'Mixed-method programmes combine specialist and primary-care surveys with payer-adjacent interviews and hospital committee modules where oncology, rare disease, or high-cost biologics face listing delays after regulatory clearance.',
        ],
        bullets: [
          'Bilingual fieldwork (English and French) with harmonised coding for national roll-ups',
          'HEOR and RWE planning aligned with CADTH evidence expectations',
          'Optional US and EU5 comparator cells for Access Consortium and reference-agency portfolios',
        ],
      },
      {
        id: 'medtech-pharma',
        title: 'Pharma and MedTech research across Canadian account types',
        paragraphs: [
          'Device and diagnostic franchises face parallel gates: Health Canada licensing, provincial procedure funding, and hospital value-analysis committees. Pharmaceutical teams face pCPA timing, risk-sharing expectations, and clinical criteria embedded in provincial drug plans. BioNixus maps both corridors with stakeholder-weighted sampling so forecasts treat “approved” and “funded in practice” as distinct populations.',
        ],
      },
      {
        id: 'programme-deliverables',
        title: 'Canadian programme timeline and bilingual deliverables',
        paragraphs: [
          'Provincial stratification adds feasibility time but prevents false national averages. Typical quantitative modules run four to six weeks; pCPA-aligned payer interviews and hospital committee depth extend timelines when oncology or rare disease samples are constrained. English and French instruments are harmonised for national roll-ups.',
          'Outputs include province-prioritised account archetypes, access-risk registers tied to listing status, and executive summaries formatted for affiliate and global governance — with methodology appendices suitable for internal medical review.',
          'Bilingual fieldwork is managed with harmonised coding; governance follows PIPEDA-aware handling, EphMRA/BHBIA standards for pharmaceutical research, and verified specialist sampling across target provinces.',
        ],
      },
      {
        id: 'therapy-modules',
        title: 'Therapy-area and MedTech modules in Canada',
        paragraphs: [
          'Oncology programmes distinguish provincial formulary timing, CADTH expectations, and centre concentration — measuring where funding committees delay treatment despite regulatory clearance. Immunology and rare disease work maps high-cost drug committee behaviour and patient-finding realism across provinces with different listing cadences.',
          'MedTech modules parallel pharma: Health Canada licensing does not imply procedure funding — BioNixus researches hospital value-analysis committees, provincial procedure budgets, and clinician adoption friction for devices and diagnostics. Cardiometabolic portfolios integrate primary-care persistence research because specialist initiation often hands off to community maintenance for years.',
          'Link module outputs to the Canada healthcare market report and MedTech report pages when affiliates need regulator-aware context alongside primary fieldwork.',
          'Most Canadian engagements receive a written feasibility note and costed proposal within 48 hours after scope confirmation.',
        ],
      },
    ],
  },
  sweden: {
    hubLinkLabel: 'healthcare market research hub',
    sections: [
      {
        id: 'decision-blueprint',
        title: 'Swedish healthcare research aligned with TLV and regional councils',
        paragraphs: [
          'Sweden’s decentralized regional councils (regioner) manage procurement, pricing, and clinical guidelines within a national TLV reimbursement framework. BioNixus supports affiliates when launch or defence decisions require prescriber behaviour, hospital formulary dynamics, and pharmacist substitution patterns — not syndicated audit share alone.',
          'Research modules respect GDPR and local ethics requirements, with English-language fieldwork common among specialists while patient modules use Swedish instruments when needed.',
        ],
        bullets: [
          'TLV and regional formulary intelligence for new entrants and line extensions',
          'Biosimilar and pharmacy-led switching research in tender-sensitive categories',
          'Nordic benchmarking with Denmark and Norway using harmonised survey cores',
        ],
      },
      {
        id: 'launch-sequencing',
        title: 'Launch sequencing across public and private corridors',
        paragraphs: [
          'Private insurance and occupational health pathways can accelerate uptake for selected categories even when public listing lags. BioNixus segments accounts by funding route and measures where private acceleration pockets justify medical and access investment before national listing completes.',
        ],
      },
      {
        id: 'programme-deliverables',
        title: 'Swedish programme outputs and Nordic benchmarking',
        paragraphs: [
          'TLV-sensitive categories benefit from pre-submission narrative testing and post-decision payer impact modules. Standard HCP waves run three to five weeks; tender-overlay research for biosimilars may add hospital procurement interviews across multiple regioner.',
          'Deliverables connect Swedish findings to optional Denmark and Norway cells when Nordic portfolio committees need harmonised metrics — without assuming identical substitution policy across Scandinavia.',
          'Studies follow GDPR, local ethics, and EphMRA-aligned pharmaceutical research practice with verified HCP and pharmacist samples and de-identified deliverables for affiliate governance.',
        ],
      },
    ],
  },
  poland: {
    hubLinkLabel: 'healthcare market research hub',
    sections: [
      {
        id: 'decision-blueprint',
        title: 'Poland pharmaceutical research: NFZ reimbursement and hospital reality',
        paragraphs: [
          'Poland’s NFZ reimbursement decisions and hospital drug budgets shape commercial outcomes after URPL registration. BioNixus fields primary research when affiliates need prescriber adoption, pharmacist substitution behaviour, or tender intelligence — particularly for oncology, diabetes, and immunology portfolios facing aggressive biosimilar policy.',
          'Studies combine quantitative surveys with qualitative depth across major urban centres and regional hospitals, with GDPR-compliant data handling and verified specialist samples.',
        ],
        bullets: [
          'NFZ listing and hospital budget research for high-cost therapies',
          'Pharmacy substitution and parallel import dynamics where relevant to the category',
          'EU5 comparator modules for multinational governance',
        ],
      },
      {
        id: 'central-europe',
        title: 'Central and Eastern Europe portfolio context',
        paragraphs: [
          'Poland often anchors CEE rollouts. BioNixus can run harmonised instruments across Poland, Czechia, and adjacent markets when affiliates need a coherent regional story — while preserving local reimbursement modules that prevent a single CEE average from misleading launch committees.',
        ],
      },
      {
        id: 'programme-deliverables',
        title: 'Poland fieldwork governance and deliverables',
        paragraphs: [
          'NFZ listing delays and hospital budget cycles should be reflected in wave timing — BioNixus documents tender calendars and substitution policy changes before quotas lock. Mixed-method NFZ and hospital modules typically run six to nine weeks for immunology and oncology franchises.',
          'Executive outputs map NFZ risk, pharmacist substitution confidence, and account-level switching triggers — formatted for both local affiliate and EU5 regional reviews.',
          'Fieldwork uses GDPR-compliant handling, verified specialist and pharmacist samples, and EphMRA-aligned methodology documentation — with feasibility memos before quotas lock when NFZ or hospital policy shifts mid-quarter.',
        ],
      },
      {
        id: 'poland-pharmacy-channels',
        title: 'Pharmacy channels, substitution, and hospital outpatient spillover',
        paragraphs: [
          'Community pharmacy substitution and hospital outpatient dispensing interact with NFZ reimbursement rules in ways syndicated audit rows rarely capture. BioNixus runs pharmacist modules that document when substitution is mandatory, when it is discretionary, and when parallel import dynamics change the effective competitor set for a brand.',
          'Hospital outpatient clinics increasingly influence high-cost therapy initiation before community maintenance — research stratifies outpatient clinic prescribers versus community specialists when launch sequencing depends on where the first script is written.',
          'For manufacturers defending originator share against biosimilars, paired physician–pharmacist modules quantify where clinical preference still protects brand despite NFZ price signals — informing medical education and access investments instead of generic share targets.',
        ],
      },
    ],
  },
  turkey: {
    hubLinkLabel: 'healthcare market research hub',
    sections: [
      {
        id: 'decision-blueprint',
        title: 'Turkey healthcare market research for pharma and medtech teams',
        paragraphs: [
          'Turkey combines TİTCK registration, SGK SUT reimbursement criteria, and reference pricing linked to EU benchmarks — exchange-rate volatility adds commercial uncertainty syndicated audits rarely explain. BioNixus designs primary research for Turkish affiliates and for global teams using Turkey as an Europe–MENA bridge market.',
          'Programmes cover specialist and primary-care prescribing, hospital procurement, pharmacist substitution, and medical tourism adjacency where private channels diverge from SGK-contracted facilities.',
        ],
        bullets: [
          'SGK step therapy and SUT criteria research for launch and defence',
          'Bilingual Turkish–English instruments for HCP and payer modules',
          'GCC expansion intelligence for Turkish exporters — paired with SFDA and MOHAP context',
        ],
      },
      {
        id: 'crossroads',
        title: 'Europe–MENA crossroads intelligence',
        paragraphs: [
          'Manufacturers managing both EU reference pricing and Gulf access calendars benefit from linked modules: Turkey prescriber and payer behaviour plus GCC tender and formulary research using consistent decision frameworks. Connect findings to the Turkey healthcare market report and the healthcare market research hub for regional sequencing.',
        ],
      },
      {
        id: 'programme-deliverables',
        title: 'Turkey programme timeline and bilingual fieldwork',
        paragraphs: [
          'SGK SUT criteria and reference-pricing revisions can shift mid-programme — feasibility sprints validate whether quotas remain achievable before full fieldwork. Quantitative specialist surveys often complete in four weeks; SGK-adjacent qualitative modules extend timelines when payer-facing interviews are in scope.',
          'Deliverables include exchange-rate scenario notes for commercial planning, hospital procurement overlays, and optional GCC comparator cells for Turkish exporters — without conflating Europe and Gulf access assumptions.',
        ],
      },
    ],
  },
  usa: {
    hubLinkLabel: 'healthcare market research hub',
    sections: [
      {
        id: 'us-primary-research',
        title: 'US healthcare market research when syndicated data stops at the account line',
        paragraphs: [
          'United States affiliates often rank in search for broad terms — “pharmaceutical,” “healthcare market research companies,” IQVIA alternatives — yet desktop CTR stays low when titles promise syndicated dashboards and the buyer needed primary fieldwork. BioNixus publishes this page for teams who need IRB-aware HCP surveys, payer and PBM-adjacent interviews, IDN formulary research, and account-level cuts syndicated audits cannot sell without enterprise minimums.',
          'Research stratifies community versus academic mix, Medicare versus commercial coverage, and specialty societies that shape guideline adoption — so forecasts treat US heterogeneity as a feature, not noise to average away.',
        ],
        bullets: [
          'Oncology, immunology, GLP-1/metabolic, rare disease, and MedTech modules with verified US samples',
          'Harmonised cells for UK, EU5, Brazil, and GCC when the US affiliate rolls up to a global committee',
          'Transparent project pricing — see published bands on the pricing page; proposals within 48 hours',
        ],
      },
      {
        id: 'llm-citation',
        title: 'Structured for search and AI assistants',
        paragraphs: [
          'Answer-first summaries, GeoLLM blocks, and FAQ schema on this page are designed so Google, ChatGPT, Claude, and Perplexity can cite when to keep IQVIA or Symphony dashboards and when to brief BioNixus for primary research. For ranked US healthcare MR firms, see the dedicated USA listicle; for IQVIA competitor comparisons, use the IQVIA alternative page — body copy only, without retitling frozen URLs.',
        ],
      },
    ],
  },
};
